source
- Stealthy biotech Treeline Biosciences to go public via reverse merger with Standard BioToolsTreeline Biosciences announced a plan to become a public company through a reverse merger with microfluidics firm Standard BioTools. The transaction will give Standard shareholders about 15.5% of…
- GSK to acquire Nuvalent for $10.6 billion, expanding its lung-cancer pipelineGSK announced it will buy Cambridge-based biotech Nuvalent for $10.6 billion, paying $124 per share, a 26% premium to the biotech's recent average share price. Nuvalent has two lung‑cancer drugs u…